NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.95 -0.27 (-3.28 %) (As of 05/22/2019 04:00 PM ET)Previous Close$8.22Today's Range$7.95 - $8.2652-Week Range$3.60 - $17.60Volume2,388 shsAverage Volume190,178 shsMarket Capitalization$91.42 millionP/E RatioN/ADividend YieldN/ABeta1.72 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company was founded in 2008 and is based in Cambridge, Massachusetts. Receive CATB News and Ratings via Email Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CATB Previous Symbol CUSIPN/A CIK1454789 Webhttp://www.catabasis.com/ Phone617-349-1971Debt Debt-to-Equity Ratio0.01 Current Ratio12.25 Quick Ratio9.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$500,000.00 Price / Sales182.83 Cash FlowN/A Price / Cash FlowN/A Book Value$4.34 per share Price / Book1.83Profitability EPS (Most Recent Fiscal Year)($5.12) Net Income$-25,870,000.00 Net MarginsN/A Return on Equity-56.70% Return on Assets-51.28%Miscellaneous Employees24 Outstanding Shares11,499,000Market Cap$91.42 million Next Earnings Date8/8/2019 (Estimated) OptionableNot Optionable Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions What is Catabasis Pharmaceuticals' stock symbol? Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB." When did Catabasis Pharmaceuticals' stock split? How did Catabasis Pharmaceuticals' stock split work? Catabasis Pharmaceuticals's stock reverse split on Monday, December 31st 2018. The 1-10 reverse split was announced on Monday, December 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 28th 2018. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. How were Catabasis Pharmaceuticals' earnings last quarter? Catabasis Pharmaceuticals Inc (NASDAQ:CATB) released its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.02. View Catabasis Pharmaceuticals' Earnings History. When is Catabasis Pharmaceuticals' next earnings date? Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Catabasis Pharmaceuticals. What price target have analysts set for CATB? 3 analysts have issued 12-month target prices for Catabasis Pharmaceuticals' shares. Their predictions range from $15.00 to $77.00. On average, they anticipate Catabasis Pharmaceuticals' share price to reach $36.6667 in the next year. This suggests a possible upside of 361.2% from the stock's current price. View Analyst Price Targets for Catabasis Pharmaceuticals. What is the consensus analysts' recommendation for Catabasis Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catabasis Pharmaceuticals. Has Catabasis Pharmaceuticals been receiving favorable news coverage? Media headlines about CATB stock have been trending negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Catabasis Pharmaceuticals earned a news impact score of -2.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. Who are some of Catabasis Pharmaceuticals' key competitors? Some companies that are related to Catabasis Pharmaceuticals include Kezar Life Sciences (KZR), Sinovac Biotech (SVA), Prothena (PRTA), Innate Pharma (IPHYF), OptiNose (OPTN), Abeona Therapeutics (ABEO), Rigel Pharmaceuticals (RIGL), Beyondspring (BYSI), Keryx Biopharmaceuticals (KERX), AMAG Pharmaceuticals (AMAG), Theratechnologies (THERF), Xeris Pharmaceuticals (XERS), AC Immune (ACIU), BIOFRONTERA AG/ADR (BFRA) and Five Prime Therapeutics (FPRX). What other stocks do shareholders of Catabasis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catabasis Pharmaceuticals investors own include G-III Apparel Group (GIII), Synergy Pharmaceuticals (SGYP), Corbus Pharmaceuticals (CRBP), ACADIA Pharmaceuticals (ACAD), Genocea Biosciences (GNCA), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Lexicon Pharmaceuticals (LXRX) and TherapeuticsMD (TXMD). Who are Catabasis Pharmaceuticals' key executives? Catabasis Pharmaceuticals' management team includes the folowing people: Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 51)Dr. Andrew J. Nichols, Chief Scientific Officer (Age 58)Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 62)Mr. Noah Clauser, VP of Fin. & ControllerMs. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 54) When did Catabasis Pharmaceuticals IPO? (CATB) raised $60 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers. Who are Catabasis Pharmaceuticals' major shareholders? Catabasis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Federated Investors Inc. PA (19.04%), Dimensional Fund Advisors LP (1.29%), Renaissance Technologies LLC (1.08%), Oppenheimer & Co. Inc. (0.80%), Oxford Asset Management LLP (0.65%) and RMB Capital Management LLC (0.56%). View Institutional Ownership Trends for Catabasis Pharmaceuticals. Which institutional investors are buying Catabasis Pharmaceuticals stock? CATB stock was purchased by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Dimensional Fund Advisors LP, Renaissance Technologies LLC, Oxford Asset Management LLP, RMB Capital Management LLC, BlackRock Inc., Oppenheimer & Co. Inc. and Virtu Financial LLC. View Insider Buying and Selling for Catabasis Pharmaceuticals. How do I buy shares of Catabasis Pharmaceuticals? Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Catabasis Pharmaceuticals' stock price today? One share of CATB stock can currently be purchased for approximately $7.95. How big of a company is Catabasis Pharmaceuticals? Catabasis Pharmaceuticals has a market capitalization of $91.42 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-25,870,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Catabasis Pharmaceuticals employs 24 workers across the globe. What is Catabasis Pharmaceuticals' official website? The official website for Catabasis Pharmaceuticals is http://www.catabasis.com/. How can I contact Catabasis Pharmaceuticals? Catabasis Pharmaceuticals' mailing address is One Kendall Square Bldg. 1400E Suite B14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected] MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 352 (Vote Outperform)Underperform Votes: 230 (Vote Underperform)Total Votes: 582MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: What is a short straddle? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.